systemic sclerosis-associated pulmonary hypertension why disease-specific composite endpoints are needed系统性sclerosis-associated肺动脉高压为什么特异复合端点是必要的.pdf

Denton et al. Arthritis Research Therapy 2011, 13:114 /content/13/3/114 CO M M E N TA R Y Systemic sclerosis-associated pulmonary hypertension: why disease-specii c composite endpoints are needed 1 2 3 4 5 6 Christopher P Denton* , Jerome Avouac , Frank Behrens , Daniel E Furst , Ivan Foeldvari , Marc Humbert , 7 8 9 10 11 12 Doerte Huscher , Otylia Kowal-Bielecka , Marco Matucci-Cerinic , Peter Nash , Christian F Opitz , David Pittrow , 13 14 15 Lewis J Rubin , James R Seibold and Oliver Distler patients with PAH related to SSc (PAH-SSc) show Abstract blunted responses to therapy when compared with those Pulmonary arterial hypertension (PAH) is a serious with idiopathic PAH, including key measures of outcome complication of systemic sclerosis (SSc). In clinical trials such as the six-minute walk test, time to clinical PAH-SSc has been grouped with other forms, including worsening and survival [3]. h e very presence of SSc idiopathic PAH. The primary endpoint for most provides an enriched population at high risk of PAH and pivotal studies was improvement in exercise capacity. should off er the opportunity for early diagnosis, yet However, composite clinical endpoints that better registry and centre-based data reveal no improvement in rel ect long-term outco